Mandate

Vinge has advised KCG in connection with the acquisition of Neonet

September 16, 2016

Vinge has advised KCG Holdings, Inc. on its acquisition of Neonet Securities AB from inter alios Hay Tor Capital LLP, KAS Bank N.V., Nordic Capital / Cidron Delphi Intressenter AB and Neonet management. Neonet is a Swedish independent capital markets services provider offering a comprehensive suite of advanced algorithmic trading, smart order routing and sales.

KCG is a leading independent securities firm offering investors a range of services designed to address trading needs across asset classes, product types and time zones. The acquisition is a strategic supplement to KCG’s business concept and will strengthen KCG’s reach in continental Europe and will enable both KCG’s and Neonet’s clients to access a more complete range of international execution services and capabilities.

The acquisition was granted the relevant approvals from the Swedish Financial Supervisory Authority on 6 September and was completed on 14 September 2016.

Vinge’s team consisted of among others partners Daniel Rosvall (M&A) and Emma Stuart-Beck (Financial Services) as well as associates Samra Baytar (M&A), Caroline Krassén and Henrik Schön (Financial Services).


 

Related

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.
June 20, 2024

Vinge advises Axcel VI and the Currentum in connection with the acquisition of Elektro-Emanuel

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elektro-Emanuel AB. The company carries out electrical installations for both companies and private individuals and has offices in four cities in western Sweden.
June 19, 2024

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.
June 19, 2024